List view / Grid view
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...
23 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients...
Researchers are developing a new kind of treatment, an antibody-based drug called 3BNC117, that may provide a better strategy for long-term control of HIV...
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
13 April 2016 | By Victoria White, Digital Content Producer
A study has shown that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens...
7 April 2016 | By Victoria White, Digital Content Producer
Enrolment has started for two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection, VRC01...
30 March 2016 | By Victoria White
Darunavir/cobicistat is indicated for use in combination with other antiretroviral medications, for treating adults with HIV-1...
26 February 2016 | By Victoria White
The LATTE-2 study showed that a regimen of two investigational long-acting, intramuscular (IM) formulations of HIV medicines had comparable antiviral activity to 3-drug oral antiretroviral therapy in HIV-1 infected adults...
26 February 2016 | By Victoria White
Descovy is an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents in combination with other HIV antiretroviral agents...
24 February 2016 | By Victoria White
At Week 48 of the study, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens in HIV-1 infected adult patients...
23 February 2016 | By Victoria White
ONCEMRK is evaluating an investigational once-daily formulation of Isentress (raltegravir), known as raltegravir 600 mg, for previously untreated HIV-1 infected adults...
1 February 2016 | By Victoria White
The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP...
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
18 December 2015 | By Victoria White
ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...
